Study Title
A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) plus Carboplatin-paclitaxel versus Placebo plus Carboplatin-paclitaxel in Patients with Recurrent or Primary Advanced Endometrial Cancer
Purpose
Determine the efficacy and safety of dostarlimab plus carboplatin-paclitaxel versus placebo plus carboplatin-paclitaxel in patients with recurrent or primary advanced (Stage III or IV) endometrial cancer.
Eligibility
Study Process
Trial Details
Investigator:
Destin Black, M.D.
IRB:
Western
IRB Number:
Trial Type:
NA
Sponsor:
Tesaro
Contact Information:
Gynecologic Oncology Associates
(318) 212-8727
http://www.wkgynonc.com